Book Cover
Home  |   Healthcare   |  Cholera Vaccines Market

Cholera Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (Oral Cholera Vaccines, Injectable Cholera Vaccines), By Application (Hospitals & Clinics, Research and Academic Laboratories, Others), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Cholera Vaccines Market Overview

The global Cholera Vaccines Market is projected to expand steadily from USD 206.24 Million in 2026 to USD 576.79 Million by 2035, representing a CAGR of 12.11% during 2026-2035.

The Cholera Vaccines Market is evolving as recurring outbreaks, humanitarian emergencies, and inadequate sanitation increase demand for preventive immunization. Oral Cholera Vaccines represent an indicative 95% of product demand, reflecting their established role in outbreak response and targeted prevention. International health organizations are rebuilding vaccine availability following prolonged shortages that restricted preventive campaigns. Global supply improvements have allowed preventive vaccination activities to resume, although simultaneous outbreaks continue to pressure inventories. Current procurement is concentrated around qualified oral vaccine products, making the supplier base narrower than the broader pharmaceutical company landscape. 

The United States Cholera Vaccines Market primarily serves specialized travel medicine and international immunization requirements rather than widespread domestic vaccination programs. North America represents an indicative 15% of global market demand, supported by travel vaccination services, established regulatory oversight, and biomedical research activities. United States healthcare providers evaluate vaccination according to destination risks, eligibility, and current clinical recommendations. Emergent BioSolutions markets Vaxchora, an oral vaccine indicated for eligible travelers, while other vaccines serve different international markets and procurement arrangements. American research institutions also contribute to vaccine evaluation and infectious disease surveillance. 

Global Cholera Vaccines Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Increasing cholera outbreaks and renewed preventive immunization campaigns are strengthening global vaccine demand. Community vaccination and humanitarian programs within the Others application category account for an indicative 56% of demand, reflecting widespread public health requirements.
  • Major Market Restraint: Limited qualified manufacturing capacity, stringent regulatory requirements, and complicated vaccine distribution restrict market expansion. Injectable Cholera Vaccines represent an indicative 5% of the report's product segmentation, reflecting their limited relevance to contemporary immunization programs.
  • Emerging Trends: Simplified oral vaccine formulations, improved manufacturing processes, and advanced clinical evaluation are reshaping vaccine development. Research and Academic Laboratories represent an indicative 12% of application demand, supporting immunization research, effectiveness assessment, and product innovation.
  • Regional Leadership: Middle East and Africa leads the Cholera Vaccines Market with an indicative 42% demand share, supported by recurring cholera outbreaks, humanitarian vaccination campaigns, inadequate sanitation infrastructure, and increasing preventive immunization requirements.
  • Competitive Landscape: Valneva SE leads the report's supplied-company competitive assessment with an indicative 14% market share, supported by its Dukoral oral cholera vaccine, established travel vaccination business, international distribution capabilities, and vaccine development expertise.
  • Market Segmentation: Oral Cholera Vaccines dominate product segmentation with an indicative 95% market share, supported by widespread use in preventive immunization programs, outbreak response campaigns, humanitarian vaccination initiatives, and specialized traveler protection.
  • Recent Development: Emergent BioSolutions announced a vaccine manufacturing partnership with Substipharm Biologics in April 2026, strengthening its broader vaccine production capabilities alongside its Vaxchora cholera vaccine business and indicative 11% competitive market share.

Restoration of preventive cholera vaccination is reshaping international procurement and emergency preparedness strategies. Oral Cholera Vaccines represent an indicative 95% of product demand, supported by improved availability and established mass immunization procedures. Following extended global shortages, international organizations resumed preventive campaigns while retaining emergency response capacity. A simplified oral vaccine formulation has helped expand manufacturing output and reduce production complexity. Public health programs increasingly evaluate vaccination alongside surveillance and sanitation improvements to address communities facing persistent transmission. 

Vaccine research increasingly focuses on practical campaign effectiveness and the operational requirements of vulnerable populations. Research and Academic Laboratories represent an indicative 12% of application demand, reflecting continued study of vaccine protection, dosing strategies, and deployment conditions. Researchers evaluate immune responses and effectiveness across population groups while examining opportunities for improved formulations. Operational studies also assess cold-chain management, vaccine acceptance, and campaign coverage. 

Cholera Vaccines Market Dynamics

Driver

"Recurring outbreaks and preventive immunization needs sustain vaccine demand."

Recurring cholera outbreaks remain the principal driver of vaccine procurement across vulnerable communities. Others accounts for an indicative 56% of application demand, reflecting government vaccination campaigns, humanitarian operations, and community immunization programs. Cholera spreads through contaminated food and water, making displaced populations and communities with inadequate sanitation particularly vulnerable. Public health authorities use vaccination to reduce immediate disease risks while strengthening surveillance and access to treatment. Global stockpile arrangements support rapid vaccine allocation when outbreaks are confirmed. 

Healthcare facilities also support vaccination through clinical consultation, immunization services, and management of patients at risk. Hospitals & Clinics represent an indicative 32% of application demand, reflecting institutional participation in vaccination and travel health services. Medical professionals evaluate vaccine eligibility according to product indications and the conditions in affected regions. Healthcare institutions may support outbreak planning, patient education, and administration of vaccines through authorized programs. Manufacturers must provide suitable handling guidance and consistent product information. 

Restraint

"Concentrated manufacturing and logistical demands constrain availability."

Limited manufacturing diversity remains a major market restraint because large-scale outbreak procurement depends on a small number of appropriately qualified products. Injectable Cholera Vaccines represent an indicative 5% of the defined segmentation, reflecting limited contemporary use compared with established oral alternatives. Historical injectable formulations are not the standard approach for current international mass vaccination campaigns. Manufacturers entering this market must undertake extensive development, clinical evaluation, and regulatory qualification. Expanding production also requires specialized equipment and dependable quality systems. 

Cold-chain and distribution requirements create additional barriers when vaccines must reach remote or unstable environments. Others represents an indicative 56% of application demand, highlighting the operational importance of humanitarian and community vaccination programs. Transport interruptions, limited refrigeration, conflict, and population displacement can complicate delivery schedules. International stockpile release mechanisms require coordination among procurement agencies, governments, and vaccination partners. Local programs must also manage staff availability and community communication. 

Opportunity

"Improved vaccine supply creates opportunities for preventive protection."

Renewed preventive vaccination campaigns provide opportunities for manufacturers and healthcare partners involved in international cholera control. Middle East and Africa represents an indicative 42% of market demand, reflecting substantial outbreak exposure and requirements for coordinated public health intervention. Expanded oral vaccine production has improved the ability to allocate doses before outbreaks become widespread. Manufacturers with qualified facilities can contribute to more resilient procurement systems and predictable supply schedules. Opportunities also extend to distribution support and vaccine quality monitoring. Sustained development requires investment in water and sanitation infrastructure alongside immunization. 

Travel medicine provides a distinct opportunity for manufacturers serving individuals visiting regions with recognized cholera risks. Hospitals & Clinics account for an indicative 32% of application demand, supported by vaccination consultation and specialized immunization services. Products including Dukoral and Vaxchora serve defined markets under their respective regulatory authorizations. Manufacturers must communicate product-specific eligibility, administration requirements, and protection limitations clearly. Healthcare providers can improve traveler understanding of vaccination alongside safe food and drinking-water practices. 

Challenge

"Balancing outbreak response with long-term prevention remains difficult."

Balancing emergency and preventive vaccine allocation remains challenging during periods of simultaneous cholera outbreaks. Others represents an indicative 56% of application demand, emphasizing the importance of coordinated community and humanitarian vaccination programs. Emergency responses can require rapid procurement when affected populations have limited access to healthcare or safe drinking water. Public health organizations must prioritize available doses using epidemiological evidence and established allocation criteria. Short-term vaccination can reduce immediate vulnerability but cannot replace permanent improvements in sanitation.

Maintaining public trust while communicating vaccine protection is another significant challenge. Research and Academic Laboratories account for an indicative 12% of demand, reflecting the importance of evidence on duration of protection and appropriate vaccination strategies. Different vaccine products have distinct characteristics and recommended administration schedules. Researchers must evaluate effectiveness under real-world conditions and across relevant age groups. Health agencies also need accessible communications explaining why vaccination complements rather than replaces clean water and prompt medical treatment. 

Cholera Vaccines Market Segmentation

Global Cholera Vaccines Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Oral Cholera Vaccines: Oral Cholera Vaccines form the foundation of contemporary immunization strategies because they can be administered without injections and are suitable for organized population campaigns. The segment represents an indicative 95% of product demand, reflecting established international procurement and clinical use. WHO-prequalified oral products include Dukoral, Euvichol-Plus, and Euvichol-S, although their indications and procurement arrangements differ. Products intended for international stockpile use support prevention and emergency outbreak response. Manufacturers must maintain validated production, appropriate regulatory documentation, and reliable distribution conditions. Dosing recommendations vary according to product and campaign circumstances. 

Injectable Cholera Vaccines: Injectable Cholera Vaccines represent a historical product category with limited relevance to contemporary international cholera prevention. This category is assigned an indicative 5% within the report's analytical segmentation, rather than reflecting verified current procurement volumes. Older injectable formulations have largely been displaced by oral vaccines offering more practical administration and established recommendations. Modern cholera campaigns rely on approved oral products rather than routine injectable immunization. Any renewed injectable development would require suitable clinical evidence, regulatory assessment, and demonstrated advantages. Production considerations include manufacturing consistency, patient acceptability, and operational complexity. 

By Applications

Hospitals & Clinics: Hospitals & Clinics support cholera vaccination through medical assessment, travel consultation, authorized immunization services, and participation in public health programs. The category represents an indicative 32% of application demand, reflecting institutional vaccination activity within the defined report framework. Healthcare professionals assess eligibility, previous vaccination history, product requirements, and potential contraindications. Facilities may coordinate immunization with disease surveillance and patient education. Clinical settings are especially relevant to specialized traveler vaccines and selected local vaccination arrangements. Medical providers must also communicate the importance of safe food, drinking water, and prompt treatment. Institutional participation depends on local vaccination policies and the availability of licensed products.

Research and Academic Laboratories: Research and Academic Laboratories contribute to vaccine development, clinical evaluation, epidemiological surveillance, and assessment of immunization strategies. This application accounts for an indicative 12% of demand, reflecting a specialized role rather than mass vaccine administration. Researchers investigate protective immune responses, effectiveness across age groups, and opportunities to improve vaccine design. Laboratory activities can include bacterial characterization, assay development, and quality assessment. Academic partnerships also evaluate campaign outcomes and population-level protection. Research findings inform public health recommendations and manufacturing priorities. 

Others: Others primarily encompasses vaccination campaigns conducted through public health authorities, humanitarian partners, community outreach teams, and international immunization programs. The segment accounts for an indicative 56% of application demand, reflecting the central importance of population-level cholera prevention. These programs often operate in communities experiencing outbreaks, displacement, flooding, or inadequate access to safe water. Vaccination teams coordinate beneficiary identification, supply transportation, dose administration, and community education. International stockpile arrangements help allocate doses according to public health priorities. Campaign performance depends on local workforce availability, logistics, and community engagement. Demand remains closely connected to outbreak activity and renewed preventive vaccination strategies.

Cholera Vaccines Market Regional Outlook

Global Cholera Vaccines Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America represents a specialized market for cholera vaccination, primarily associated with international travel medicine and vaccine research. The region accounts for an indicative 15% of global demand within this assessment, supported by clinical vaccination services and established regulatory systems. Cholera is not routinely endemic across the United States and Canada, making domestic mass immunization unnecessary under ordinary circumstances. Healthcare providers instead assess risks for eligible international travelers. Specialized manufacturers maintain products appropriate to their approved markets. Research institutions also contribute expertise in clinical development and infectious disease prevention. Regional activity depends on travel patterns, immunization guidance, and international disease conditions.

Europe

Europe maintains an established position in cholera vaccine development, travel vaccination, and international public health support. The region holds an indicative 10% demand share, reflecting specialized clinical use rather than widespread routine vaccination. European companies have developed recognized oral products and maintain expertise in vaccine manufacturing and regulatory compliance. Healthcare services provide advice to travelers visiting areas where cholera transmission presents a recognized risk. Research organizations contribute to global vaccine development and disease monitoring. International procurement programs also benefit from European institutional funding and technical expertise. Future demand depends on travel immunization needs, overseas disease conditions, and product availability.

Asia-Pacific

Asia-Pacific represents an important region for cholera vaccination through endemic disease exposure, public health programs, and manufacturing expertise. The region accounts for an indicative 29% of global demand, supported by vaccination requirements in selected South Asian and neighboring populations. Bangladesh has been an important focus of preventive vaccination planning and disease research. Regional institutions have contributed to vaccine development, technology transfer, and practical campaign evaluation. Manufacturers and health agencies seek reliable supplies that can support communities facing recurrent transmission. Agricultural flooding, population density, and uneven sanitation infrastructure influence public health priorities. Regional opportunities depend on dependable procurement and continued investment in prevention.

Middle East and Africa

Middle East and Africa leads the defined Cholera Vaccines Market because several countries face recurring outbreaks and substantial humanitarian vaccination requirements. The region represents an indicative 42% of global demand, supported by emergency immunization and preventive programs in vulnerable communities. Conflict, displacement, flooding, and limited water infrastructure can increase cholera transmission risks. Mozambique and the Democratic Republic of the Congo were among the countries prioritized when preventive vaccination resumed. International partners coordinate vaccine allocation, logistics, and community outreach. Disease prevention also requires healthcare access, surveillance, safe water, and sanitation improvements. Continued vaccination activity depends on available supplies and responsive public health systems.

Rest of the World

Rest of the World includes selected Latin American and Caribbean markets and other locations outside the principal regional classifications. This category holds an indicative 4% of global demand, reflecting localized outbreak risks and targeted vaccination requirements. Public health agencies may consider immunization where cholera transmission threatens vulnerable communities. Natural disasters, inadequate water systems, and disruptions to healthcare access can influence preventive priorities. International organizations support vaccine availability when eligible outbreaks require coordinated intervention. Procurement decisions depend on disease surveillance and available stockpile supplies. Longer-term demand remains connected to health infrastructure resilience and sustained improvements in safe water access.

List of Top Cholera Vaccines Market Companies

  • Shantha Biotechnics Private Limited
  • Valneva SE
  • PaxVax, Inc.
  • Astellas Pharma, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • Emergent BioSolutions, Inc.
  • AstraZeneca
  • Mitsubishi Tanabe Pharma Corporation

Top Two Companies with Highest Market Share

  • Valneva SE: Assigned an indicative 14% share within the supplied-company assessment, reflecting its Dukoral oral cholera vaccine and established travel medicine capabilities.
  • Emergent BioSolutions, Inc.: Assigned an indicative 11% share within the supplied-company assessment, supported by its Vaxchora product and specialized oral vaccine experience.

Investment Analysis and Opportunities

Investment opportunities in the Cholera Vaccines Market increasingly focus on qualified manufacturing capacity, reliable procurement arrangements, and improved access to preventive immunization. Oral Cholera Vaccines represent an indicative 95% of product demand, encouraging attention to scalable production and simplified vaccine formulations. International stockpile requirements create opportunities for appropriately qualified manufacturers capable of meeting demanding supply schedules. Investments in production equipment, analytical testing, and quality assurance can improve readiness for future outbreaks. Manufacturers must also maintain reliable ingredient supplies and suitable regulatory documentation. Market entry remains challenging because procurement decisions depend on established product qualifications. 

Vaccination programs in vulnerable communities offer opportunities for better logistics, disease monitoring, and implementation support. Middle East and Africa represents an indicative 42% of demand, reflecting the scale of outbreak response and preventive immunization needs. International partners increasingly emphasize vaccine availability before major outbreaks develop. Investment in cold-chain systems, training, and inventory management can support practical campaign implementation. Research institutions may also strengthen assessment of dosing strategies and vaccine effectiveness. 

New Product Development

New product development is emphasizing simplified oral vaccine formulations that can support reliable manufacturing and efficient distribution. Oral Cholera Vaccines account for an indicative 95% of product demand, highlighting the importance of improvements within established vaccine platforms. Euvichol-S demonstrates how reducing formulation complexity can support higher production output while maintaining required regulatory evaluation. Manufacturers are exploring better process control, stable ingredient sourcing, and efficient packaging arrangements. Product development must include appropriate clinical evidence and rigorous quality testing. International agencies seek reliable products suitable for preventive and emergency vaccination programs. 

Research initiatives also examine protective immune responses, vaccine administration requirements, and effectiveness across different populations. Research and Academic Laboratories represent an indicative 12% of application demand, supporting continued investigation of cholera vaccine characteristics. Improved clinical evaluation methods can help manufacturers understand protection duration and suitability for different public health settings. Researchers are studying practical vaccination strategies and opportunities to simplify implementation. Vaccine development requires carefully controlled manufacturing, clinical assessment, and regulatory review. 

Five Recent Developments

  • March 2026 – GlaxoSmithKline plc (GSK): GSK received expanded United States FDA approval for its Arexvy vaccine for adults aged 18 to 49 at increased risk of severe respiratory syncytial virus disease. The approval strengthened its broader vaccine portfolio but was not a cholera-specific development.
  • April 2026 – Emergent BioSolutions, Inc.: Emergent BioSolutions announced a strategic manufacturing partnership with Substipharm Biologics to support Japanese encephalitis vaccine production at its Canton facility. The agreement strengthened its vaccine manufacturing capabilities, complementing its Vaxchora cholera vaccine business and its indicative 11% competitive share in this report.
  • June 2026 – Merck & Co., Inc.: Merck received expanded United States FDA approval for CAPVAXIVE, extending its pneumococcal vaccine indication to eligible children and adolescents at increased risk. The development demonstrated continued investment in vaccine innovation outside the cholera category.
  • July 2026 – Pfizer, Inc.: Pfizer and BioNTech received European Commission authorization for their updated COVID-19 vaccine targeting the XFG variant. The approval expanded their seasonal immunization portfolio and demonstrated their capabilities in vaccine development and regulatory compliance.
  • August 2026 – Valneva SE: Valneva and Pfizer announced that the European Medicines Agency had validated the marketing authorization application for their investigational Lyme disease vaccine. The development strengthened Valneva's broader vaccine pipeline alongside its established Dukoral oral cholera vaccine business.

Report Coverage

The Cholera Vaccines Market report examines vaccine technologies, immunization applications, international procurement arrangements, and evolving public health requirements. Product coverage includes Oral Cholera Vaccines and Injectable Cholera Vaccines, distinguishing contemporary oral immunization programs from historical injectable vaccine categories. Application analysis considers Hospitals & Clinics, Research and Academic Laboratories, and Others. The assessment explores outbreak response, preventive vaccination, manufacturing capacity, clinical evaluation, distribution planning, and regulatory qualification. Attention is given to international vaccine stockpiles, community vaccination programs, and the practical conditions influencing product access. Vaccine development is considered alongside disease surveillance and the continuing importance of safe water and sanitation.

Regional analysis covers North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of the World, examining differences in cholera transmission risks, vaccination infrastructure, and procurement requirements. Competitive coverage reviews the supplied companies while distinguishing their direct cholera vaccine involvement from broader pharmaceutical and vaccine businesses. The report evaluates production investment, product development, research collaboration, and public health implementation priorities. Company announcements concerning unrelated vaccines are identified separately from cholera-specific developments. 

Cholera Vaccines Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 206.24 Million in 2026

Market Size Value By

USD 576.79 Million by 2035

Growth Rate

CAGR of 12.11% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Oral Cholera Vaccines
  • Injectable Cholera Vaccines

By Application :

  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Cholera Vaccines Market is expected to reach USD 576.79 Million by 2035.

The Cholera Vaccines Market is expected to exhibit a CAGR of 12.11% by 2035.

Shantha Biotechnics Private Limited, Valneva SE, PaxVax, Inc., Astellas Pharma, Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Emergent BioSolutions, Inc., AstraZeneca, Mitsubishi Tanabe Pharma Corporation

In 2026, the Cholera Vaccines Market value will reach at USD 206.24 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified